Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd., an Australian firm focusing on cancer and fibrosis therapies, has announced a change in the interest of its Director, Dr. Christopher Burns. Dr. Burns has acquired 586,321 ordinary shares at $0.062 each, which adds to his substantial holdings in the company. This move reflects continued confidence in Amplia’s development focus, particularly in fibrotic cancers like pancreatic cancer and chronic diseases like idiopathic pulmonary fibrosis.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
